EGFR and metastatic colorectal cancer: The survival of metastatic colorectal cancer (mCRC) patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti–epidermal growth factor receptor (EGFR), and antiangiogenic agents associated with chemotherapy (fluoropyrimidines, oxaliplatin, and irinotecan)3.